BR0016801A - Preparação antidiabética para administração oral - Google Patents
Preparação antidiabética para administração oralInfo
- Publication number
- BR0016801A BR0016801A BR0016801-7A BR0016801A BR0016801A BR 0016801 A BR0016801 A BR 0016801A BR 0016801 A BR0016801 A BR 0016801A BR 0016801 A BR0016801 A BR 0016801A
- Authority
- BR
- Brazil
- Prior art keywords
- blood sugar
- meal
- level
- oral administration
- around
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 230000003178 anti-diabetic effect Effects 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 239000008280 blood Substances 0.000 abstract 5
- 210000004369 blood Anatomy 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 235000012054 meals Nutrition 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 abstract 1
- 229960000698 nateglinide Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
"PREPARAçãO ANTIDIABéTICA PARA ADMINISTRAçãO ORAL". Preparações compreendendo uma droga de liberação sustentada, que é capaz de diminuir o nível de açúcar sang³íneo de diabéticos após refeição para em torno do níveo normal, ou uma mistura de uma droga de liberação lenta, que é capaz de diminuir o nível de açúcar do sangue após refeição para em torno do nível normal, com uma droga de liberação rápida, desse modo diretamente baixando tanto o nível de açúcar do sangue após refeição como o nível de açúcar do sangue em jejum, respectivamente para os níveis normais, utilizando-se uma única preparação. E particularmente preferível que a droga capaz de abaixar o nível de açúcar do sangue após refeição para em torno do nível normal seja nateglinida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP37495999 | 1999-12-28 | ||
JP2000085159 | 2000-03-24 | ||
PCT/JP2000/009281 WO2001047557A1 (fr) | 1999-12-28 | 2000-12-27 | Preparations orales pour diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0016801A true BR0016801A (pt) | 2002-09-24 |
Family
ID=26582645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0016801-7A BR0016801A (pt) | 1999-12-28 | 2000-12-27 | Preparação antidiabética para administração oral |
Country Status (22)
Country | Link |
---|---|
US (2) | US7022339B2 (pt) |
EP (2) | EP1616561B1 (pt) |
JP (2) | JP4822039B2 (pt) |
KR (1) | KR20020063282A (pt) |
CN (1) | CN1437483A (pt) |
AT (2) | ATE310507T1 (pt) |
AU (1) | AU2226901A (pt) |
BR (1) | BR0016801A (pt) |
CA (1) | CA2395993A1 (pt) |
CZ (1) | CZ20022294A3 (pt) |
DE (2) | DE60024320T2 (pt) |
ES (2) | ES2248159T3 (pt) |
HK (1) | HK1049622A1 (pt) |
HU (1) | HUP0204109A3 (pt) |
IL (1) | IL150294A0 (pt) |
MX (1) | MXPA02006443A (pt) |
NO (1) | NO20023035L (pt) |
PL (1) | PL356300A1 (pt) |
PT (1) | PT1616561E (pt) |
RU (1) | RU2002120498A (pt) |
SK (1) | SK9292002A3 (pt) |
WO (1) | WO2001047557A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4822039B2 (ja) | 1999-12-28 | 2011-11-24 | 味の素株式会社 | 経口投与用糖尿病薬製剤 |
SK14922002A3 (sk) * | 2000-03-17 | 2003-04-01 | Ajinomoto Co., Inc. | Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru |
MXPA03003483A (es) * | 2000-10-18 | 2003-07-14 | Ajinomoto Kk | Procedimiento para la preparacion de acilfenilalaninas. |
JP4114200B2 (ja) * | 2000-10-18 | 2008-07-09 | 味の素株式会社 | ナテグリニド結晶の製造方法 |
DE60138476D1 (de) * | 2000-10-24 | 2009-06-04 | Ajinomoto Kk | Nateglinid enthaltende hydrophile arzneimittelpräparate |
CA2426745C (en) * | 2000-10-24 | 2009-09-15 | Ajinomoto Co., Inc. | Methods for producing nateglinide b-type crystals |
WO2002034254A1 (fr) * | 2000-10-24 | 2002-05-02 | Ajinomoto Co.,Inc. | Preparations contenant du nateglinide |
FR2816840B1 (fr) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
CN1247194C (zh) * | 2002-08-27 | 2006-03-29 | 石药集团中奇制药技术(石家庄)有限公司 | 一种那格列奈包合物 |
EP1537880A4 (en) * | 2002-09-11 | 2009-07-01 | Takeda Pharmaceutical | PREPARATION FOR PROLONGED RELEASE |
EP1562557B2 (en) | 2002-11-01 | 2016-11-16 | University of Medicine and Dentistry of New Jersey | Geodate delivery vehicles |
WO2005013964A1 (ja) | 2003-08-08 | 2005-02-17 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
WO2005016315A1 (en) * | 2003-08-14 | 2005-02-24 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler |
WO2005020979A1 (en) * | 2003-09-03 | 2005-03-10 | Ranbaxy Laboratories Limited | A process for the preparation of pharmaceutical compositions of nateglinide |
US7611693B2 (en) * | 2003-09-17 | 2009-11-03 | Board Of Regents, The Univerisity Of Texas System | Mechanism-based targeted pancreatic beta cell imaging and therapy |
US20070219250A1 (en) * | 2003-11-28 | 2007-09-20 | Romi Singh | Pharmaceutical Compositions of Nateglinide |
WO2005094812A1 (ja) * | 2004-04-01 | 2005-10-13 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
CN100455279C (zh) * | 2004-04-29 | 2009-01-28 | 美时化学制药股份有限公司 | 口服延迟释放锭剂组成物及其制法 |
KR101340946B1 (ko) * | 2004-08-04 | 2013-12-13 | 알자 코포레이션 | 오름차 0차 방출 패턴을 나타내는 약물의 서방성 조성물,상기 조성물을 제조하는 방법 |
WO2006016602A1 (ja) * | 2004-08-10 | 2006-02-16 | Ajinomoto Co., Inc. | 苦味の低減したナテグリニド含有製剤 |
CN1660064B (zh) * | 2004-12-28 | 2010-09-29 | 中山大学 | 那格列奈自乳化释药系统 |
JP4974057B2 (ja) * | 2005-01-31 | 2012-07-11 | 味の素株式会社 | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
TW200815045A (en) * | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
JP6042330B2 (ja) * | 2010-07-09 | 2016-12-14 | ビーエイチヴィ ファーマ、インコーポレイテッド | レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時/遅延放出送達システム |
WO2013077819A1 (en) * | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | Pharmaceutical formulations comprising nateglinide |
US20180050096A1 (en) * | 2015-02-09 | 2018-02-22 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
CN107296954A (zh) * | 2017-06-09 | 2017-10-27 | 王丛飞 | 一种层粘连蛋白创面保护膜 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US124191A (en) * | 1872-02-27 | Improvement in woven felted fabrics for bonnets | ||
IT1226940B (it) * | 1988-09-16 | 1991-02-22 | Recordati Chem Pharm | Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide |
US5296236A (en) * | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
JP3949725B2 (ja) * | 1996-07-17 | 2007-07-25 | オーソーペディック デザインズ,インコーポレイティド | 外科用留め具組立体 |
KR100343062B1 (ko) * | 1996-11-15 | 2002-07-02 | 에가시라 구니오 | 정제 조성물 |
JPH10231242A (ja) * | 1997-02-20 | 1998-09-02 | Taiyo Yakuhin Kogyo Kk | 持続性ジクロフェナクナトリウム組成物 |
DE19710008A1 (de) * | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
CN1158071C (zh) * | 1997-05-30 | 2004-07-21 | 渗透有限公司 | 多层渗透装置 |
ZA985126B (en) * | 1997-06-13 | 1998-12-14 | Novo Nordisk As | Novel niddm regimen |
JPH11130696A (ja) * | 1997-08-27 | 1999-05-18 | Takeda Chem Ind Ltd | 経口徐放性製剤 |
JP3677156B2 (ja) * | 1997-09-05 | 2005-07-27 | 武田薬品工業株式会社 | 医薬 |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
DE19860698A1 (de) * | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
JP3691685B2 (ja) * | 1999-06-22 | 2005-09-07 | 株式会社バイオックス | 血糖値上昇抑制剤 |
US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
AR028299A1 (es) * | 1999-09-17 | 2003-05-07 | Novartis Ag | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
JP4822039B2 (ja) | 1999-12-28 | 2011-11-24 | 味の素株式会社 | 経口投与用糖尿病薬製剤 |
AU5066101A (en) * | 2000-04-13 | 2001-10-30 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
WO2002034254A1 (fr) * | 2000-10-24 | 2002-05-02 | Ajinomoto Co.,Inc. | Preparations contenant du nateglinide |
DE60138476D1 (de) * | 2000-10-24 | 2009-06-04 | Ajinomoto Kk | Nateglinid enthaltende hydrophile arzneimittelpräparate |
FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
-
2000
- 2000-12-27 JP JP2001548145A patent/JP4822039B2/ja not_active Expired - Fee Related
- 2000-12-27 SK SK929-2002A patent/SK9292002A3/sk unknown
- 2000-12-27 CZ CZ20022294A patent/CZ20022294A3/cs unknown
- 2000-12-27 MX MXPA02006443A patent/MXPA02006443A/es unknown
- 2000-12-27 BR BR0016801-7A patent/BR0016801A/pt not_active IP Right Cessation
- 2000-12-27 PL PL00356300A patent/PL356300A1/xx unknown
- 2000-12-27 PT PT05020892T patent/PT1616561E/pt unknown
- 2000-12-27 DE DE60024320T patent/DE60024320T2/de not_active Expired - Lifetime
- 2000-12-27 AU AU22269/01A patent/AU2226901A/en not_active Abandoned
- 2000-12-27 EP EP05020892A patent/EP1616561B1/en not_active Revoked
- 2000-12-27 ES ES00985918T patent/ES2248159T3/es not_active Expired - Lifetime
- 2000-12-27 DE DE60039315T patent/DE60039315D1/de not_active Expired - Lifetime
- 2000-12-27 AT AT00985918T patent/ATE310507T1/de not_active IP Right Cessation
- 2000-12-27 EP EP00985918A patent/EP1258249B1/en not_active Expired - Lifetime
- 2000-12-27 AT AT05020892T patent/ATE399000T1/de not_active IP Right Cessation
- 2000-12-27 WO PCT/JP2000/009281 patent/WO2001047557A1/ja active IP Right Grant
- 2000-12-27 CA CA002395993A patent/CA2395993A1/en not_active Abandoned
- 2000-12-27 RU RU2002120498/15A patent/RU2002120498A/ru not_active Application Discontinuation
- 2000-12-27 KR KR1020027008506A patent/KR20020063282A/ko not_active Application Discontinuation
- 2000-12-27 CN CN00819230A patent/CN1437483A/zh active Pending
- 2000-12-27 ES ES05020892T patent/ES2305977T3/es not_active Expired - Lifetime
- 2000-12-27 HU HU0204109A patent/HUP0204109A3/hu unknown
- 2000-12-27 IL IL15029400A patent/IL150294A0/xx unknown
-
2002
- 2002-06-21 NO NO20023035A patent/NO20023035L/no not_active Application Discontinuation
- 2002-06-28 US US10/183,322 patent/US7022339B2/en not_active Expired - Fee Related
-
2003
- 2003-03-11 HK HK03101753.2A patent/HK1049622A1/zh unknown
-
2005
- 2005-10-11 US US11/246,453 patent/US7488498B2/en not_active Expired - Fee Related
-
2011
- 2011-05-13 JP JP2011108428A patent/JP2011153157A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0016801A (pt) | Preparação antidiabética para administração oral | |
Watson et al. | Use of anti‐inflammatory and analgesic drugs in dogs and cats | |
BR0009770A (pt) | Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma | |
BR0115847A (pt) | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos | |
BR9909192A (pt) | Preparações galênicas de meloxicam para administração oral | |
MX9605940A (es) | Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
NO20022014L (no) | En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon | |
BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
HUP0002373A2 (hu) | Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények | |
BR0309004A (pt) | Matriz para liberação gradual, invariante e independente dos compostos ativos | |
BRPI0414907A (pt) | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas | |
ATE322260T1 (de) | Nateglinide zubereitung in tablettenform | |
ES2191329T3 (es) | Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares. | |
BR9712816A (pt) | Derivados de benzamidina e seu uso como medicamentos com uma atividade antagonista ltb4 | |
NO972211D0 (no) | Sulfonamid-substituerte kromaner, deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende kromanene | |
BR9916860A (pt) | Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma | |
WO2002034267A8 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
BR9815248A (pt) | Sistema monolìtico contendo um ou mais medicamentos, consistindo de três camadas com diferentes mecanismos de liberação | |
BR0111506A (pt) | Complexos de droga macromoleculares e composições contendo os mesmos | |
BR0308229A (pt) | Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio | |
WO1984000488A1 (en) | Improved analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
BR9915951A (pt) | Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas | |
BR0115390A (pt) | Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007. |